Company Profile
Arcturus Therapeutics Holdings Inc. Stock Price, News & Catalysts
- Ticker:
- ARCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.21 USD (-3.51%)
Close
Last updated: October 1, 2026
217M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, ARCT closed down 3.51% at $13.21. No new same-company headline was identified in the current news window.
Company overview
Messenger RNA Medicines Company
Arcturus Therapeutics develops mRNA medicines for respiratory and liver diseases. Its platform combines LUNAR lipid-mediated delivery, STARR self-amplifying RNA technology, and internal drug-substance and drug-product manufacturing expertise.
Inhaled mRNA for Cystic Fibrosis
ARCT-032 is an inhaled mRNA therapy designed to express functional CFTR protein in the lungs of people with cystic fibrosis, including those with Class I mutations who may not respond to current modulators. The program is being evaluated through daily inhaled dosing in a Phase 2 study.
Systemic mRNA for OTC Deficiency
ARCT-810 is an intravenously delivered mRNA therapy intended to restore ornithine transcarbamylase activity in people with OTC deficiency. The Phase 2 program includes adult and pediatric development and is intended to inform an end-of-Phase 2 regulatory path.
Self-Amplifying RNA Vaccine Portfolio
KOSTAIVE is the first approved self-amplifying mRNA COVID-19 vaccine and validates the company's STARR platform. Arcturus has regained global control of KOSTAIVE and a broader infectious-disease portfolio that includes influenza, RSV, and EBV programs, subject to existing regional arrangements.
Manufacturing and Development Partnerships
Arcturus works with Thermo Fisher Scientific on potential Phase 3 development and manufacturing for ARCT-032, with BARDA on pandemic influenza initiatives, and through ARCALIS on Japanese mRNA manufacturing. These relationships extend development capacity without requiring the company to build every capability internally.
Future catalysts
- Communication of Phase 2 data and the regulatory plan for ARCT-810 in the third quarter of 2026.
- Decision on advancing ARCT-032 into Phase 3 development in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. (ARCT) most recently closed at 13.21 USD, a -3.51% move versus the previous session.
What is the market cap of Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. currently has a market capitalization of 217M USD on BioPharmSignal.
What does Arcturus Therapeutics Holdings Inc. do?
Messenger RNA Medicines Company Arcturus Therapeutics develops mRNA medicines for respiratory and liver diseases. Its platform combines LUNAR lipid-mediated delivery, STARR self-amplifying RNA technology, and internal drug-substance and drug-product manufacturing expertise. Inhaled mRNA for Cystic Fibrosis ARCT-032 is an inhaled mRNA therapy designed to...
On which exchange is ARCT stock listed?
Arcturus Therapeutics Holdings Inc. (ARCT) is associated with NASDAQ, United States, Biopharma.
What is ARCT-032?
Decision on advancing ARCT-032 into Phase 3 development in the fourth quarter of 2026.
Which conditions is Arcturus Therapeutics Holdings Inc. targeting with ARCT-032?
Arcturus Therapeutics Holdings Inc. is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Arcturus Therapeutics Holdings Inc. describe recent progress with ARCT-032?
Decision on advancing ARCT-032 into Phase 3 development in the fourth quarter of 2026.
What is ARCT-810?
Systemic mRNA for OTC Deficiency ARCT-810 is an intravenously delivered mRNA therapy intended to restore ornithine transcarbamylase activity in people with OTC deficiency.